CD8A and neoplasm: This lead was maintained and even extended after tumor rechallenge, with the cured mice maintaining significantly higher percentages of CD4+ Tem cells (11.8% ± 0.2% vs. 7.7% ± 0.2%) and CD8+ Tcm cells (18.9% ± 1.5% vs. 7.4% ± 0.2%) than the controls.